84.88
1.19 (1.42%)
Previous Close | 83.69 |
Open | 83.51 |
Volume | 321,552 |
Avg. Volume (3M) | 319,027 |
Market Cap | 4,204,768,256 |
Price / Earnings (TTM) | 19.92 |
Price / Earnings (Forward) | 17.86 |
Price / Sales | 3.81 |
Price / Book | 2.35 |
52 Weeks Range | |
Earnings Date | 12 May 2025 - 16 May 2025 |
Profit Margin | 19.13% |
Operating Margin (TTM) | 31.68% |
Diluted EPS (TTM) | 4.26 |
Quarterly Revenue Growth (YOY) | 2.70% |
Quarterly Earnings Growth (YOY) | 15.10% |
Total Debt/Equity (MRQ) | 57.43% |
Current Ratio (MRQ) | 3.68 |
Operating Cash Flow (TTM) | 256.57 M |
Levered Free Cash Flow (TTM) | 191.75 M |
Return on Assets (TTM) | 6.19% |
Return on Equity (TTM) | 12.62% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
Stock | Prestige Consumer Healthcare In | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 4.0 |
Insider Activity | -1.5 |
Price Volatility | -0.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | 0.5 |
Average | 0.50 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
% Held by Insiders | 1.30% |
% Held by Institutions | 108.73% |
Ownership
Name | Date | Shares Held |
---|---|---|
Blackrock, Inc. | 31 Dec 2024 | 8,430,726 |
Vanguard Group Inc | 31 Dec 2024 | 5,690,159 |
Dimensional Fund Advisors Lp | 31 Dec 2024 | 2,907,066 |
Ariel Investments, Llc | 31 Dec 2024 | 2,762,023 |
Macquarie Group Ltd | 31 Dec 2024 | 2,309,017 |
State Street Corp | 31 Dec 2024 | 2,063,577 |
Victory Capital Management Inc | 31 Dec 2024 | 1,662,668 |
Allspring Global Investments Holdings, Llc | 31 Dec 2024 | 1,624,501 |
Geode Capital Management, Llc | 31 Dec 2024 | 1,348,745 |
Kayne Anderson Rudnick Investment Management Llc | 31 Dec 2024 | 1,087,620 |
Morgan Stanley | 31 Dec 2024 | 1,085,793 |
Invesco Ltd. | 31 Dec 2024 | 1,060,263 |
Congress Asset Management Co | 31 Dec 2024 | 908,742 |
Boston Trust Walden Corp | 31 Dec 2024 | 831,627 |
Northern Trust Corp | 31 Dec 2024 | 813,076 |
52 Weeks Range | ||
Price Target Range | ||
High | 104.00 (DA Davidson, 22.53%) | Buy |
Median | 100.00 (17.81%) | |
Low | 93.00 (Oppenheimer, 9.57%) | Buy |
Average | 99.00 (16.64%) | |
Total | 3 Buy | |
Avg. Price @ Call | 86.56 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Oppenheimer | 13 Feb 2025 | 93.00 (9.57%) | Buy | 85.68 |
Canaccord Genuity | 07 Feb 2025 | 100.00 (17.81%) | Buy | 87.00 |
DA Davidson | 07 Feb 2025 | 104.00 (22.53%) | Buy | 87.00 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
FRITZ MARY BETH | - | 86.86 | -1,678 | -145,751 |
Aggregate Net Quantity | -1,678 | |||
Aggregate Net Value ($) | -145,751 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 86.86 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
FRITZ MARY BETH | Officer | 10 Mar 2025 | Sell (-) | 1,678 | 86.86 | 145,751 |
Date | Type | Details |
---|---|---|
06 Feb 2025 | Announcement | Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook |
09 Jan 2025 | Announcement | Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earnings Results Date and ICR Conference Presentation |
06 Jan 2025 | Announcement | Prestige Consumer Healthcare Inc. Expands CFO Christine Sacco’s Role to Include Chief Operating Officer Responsibilities |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |